Balloon Mitral Valvuloplasty in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS (Indications for BMV):

• Symptomatic mitral stenosis (NYHA Class II–IV) with mitral valve area (MVA) ≤1.5 cm² and favorable valve morphology (Wilkins Score ≤8)

• Asymptomatic severe mitral stenosis (MVA ≤1.0 cm²) with evidence of pulmonary hypertension (PASP >50 mmHg at rest) or new-onset atrial fibrillation

• Patients in whom surgical risk is prohibitively high due to comorbidities (e.g., advanced COPD, severe pulmonary hypertension, elderly patients)

• Pregnant patients with severe, symptomatic mitral stenosis refractory to medical therapy (BMV is the preferred intervention given avoidance of cardiopulmonary bypass and its associated fetal risks)

• Patients with moderate MS and significant symptoms disproportionate to valve area, confirmed on exercise stress echocardiography showing a rise in mean gradient >15 mmHg or PASP >60 mmHg during exertion

• REQUIRED PRE-PROCEDURAL DIAGNOSTICS:

• Transthoracic Echocardiography (TTE): MVA by planimetry and PHT, Wilkins Score, degree of MR, PASP, LV/RV function

• Transesophageal Echocardiography (TEE): Mandatory to exclude left atrial appendage (LAA) thrombus before the procedure

• 12-Lead ECG: Rhythm assessment, atrial fibrillation burden

• Chest X-Ray: Left atrial enlargement, pulmonary vascular congestion, Kerley B lines

• Complete Blood Count, Coagulation Profile (PT/INR/aPTT), Renal Function, Liver Function Tests

• Cardiac Catheterization (selective): Right and left heart hemodynamic assessment when non-invasive data is discordant or pulmonary hypertension severity needs quantification

• Anti-Streptolysin O (ASO) titer and throat culture: To assess for active rheumatic activity requiring prophylaxis optimization

• CONTRAINDICATIONS (Absolute and Relative):

• Left atrial or left atrial appendage thrombus on TEE (absolute — procedure must be deferred until thrombus resolves with therapeutic anticoagulation, typically 3–6 months of warfarin with repeat TEE)

• Moderate-to-severe mitral regurgitation (MR grade ≥2+/4+) — BMV carries a risk of worsening MR and surgical referral is preferred

• Wilkins Score >12 — predicts suboptimal commissural splitting and increased MR risk

• Severe bicommissural calcification (symmetric calcification prevents effective leaflet splitting)

• Concomitant severe aortic or tricuspid valvular disease requiring surgical correction

• Active infective endocarditis

• Significant IAS (interatrial septal) abnormality that precludes safe transseptal puncture (e.g., prior ASD closure with device)

• Severe, irreversible pulmonary hypertension with fixed pulmonary vascular resistance (a relative contraindication — specialist assessment required)

STANDARD TECHNIQUE — INOUE BALLOON TECHNIQUE: The Inoue technique is the global gold standard for BMV, accounting for the overwhelming majority of procedures performed worldwide. Under fluoroscopic and echocardiographic guidance, the interventional cardiologist gains femoral venous access and advances a catheter to the right atrium. Transseptal puncture using a Brockenbrough needle and Mullins sheath is performed under biplane fluoroscopy and/or intracardiac or transesophageal echocardiographic guidance to cross the interatrial septum safely at the fossa ovalis. The Inoue balloon — a unique self-positioning, pressure-extensible latex balloon with three distinct diameter stages (distal, equatorial, proximal) — is advanced across the mitral valve. Sequential inflation begins with the distal portion anchoring the balloon in the subvalvular apparatus, followed by full inflation at the mitral annulus level, delivering a precisely controlled commissurotomy. The target balloon diameter is calculated using the formula: balloon diameter (mm) = patient height (cm) / 10 + 10, with stepwise dilation under careful hemodynamic and echocardiographic monitoring. Procedural success is defined as an MVA ≥1.5 cm² with MR no greater than grade 2+/4+.

ADVANCED TECHNIQUE — REAL-TIME 3D TRANSESOPHAGEAL ECHOCARDIOGRAPHY (RT-3D TEE) GUIDANCE: Leading centers in India (Mumbai, Chennai, Delhi) and the UAE (Dubai, Abu Dhabi) now perform BMV under real-time 3D TEE guidance, which provides superior visualization of the transseptal puncture site, balloon positioning relative to commissures, and immediate post-dilation assessment of commissural splitting and MR grade. This approach significantly reduces fluoroscopy time and radiation exposure, and is particularly valuable in patients with complex anatomy, prior commissurotomy, or pregnancy.

ADVANCED TECHNIQUE — INTRACARDIAC ECHOCARDIOGRAPHY (ICE)-GUIDED BMV: ICE-guided BMV eliminates the need for general anesthesia (which is otherwise required for TEE guidance), allowing the procedure to be performed under conscious sedation alone. An ICE catheter (typically 8 Fr, 64-element phased array) is positioned in the right atrium to guide transseptal puncture and monitor balloon positioning. This approach is increasingly adopted in high-volume centers and is associated with shorter procedure times and improved patient comfort.

DOUBLE-BALLOON TECHNIQUE: The double-balloon technique (using two separate balloon catheters advanced across the mitral valve) was the predecessor to the Inoue technique. It is now largely superseded by the Inoue balloon but may be used in specific anatomical scenarios where larger effective balloon dilating areas are required.

MEDICAL THERAPY (ADJUNCTIVE AND PRE-PROCEDURAL): Pre-procedure optimization includes rate control for atrial fibrillation (beta-blockers such as metoprolol succinate or ivabradine in selected cases; non-dihydropyridine calcium channel blockers as alternatives), therapeutic anticoagulation with warfarin (target INR 2.5–3.5) for at least 3 months prior if LAA thrombus risk is elevated, and diuretics (furosemide ± spironolactone) for pulmonary congestion management. Rheumatic fever prophylaxis with benzathine penicillin G continues lifelong or until age 40 (whichever is longer) per current guidelines. Post-procedure anticoagulation strategy is individualized based on rhythm and procedural outcome.

SURGICAL ALTERNATIVES (when BMV is not feasible): Open Surgical Mitral Commissurotomy (OSMC) via median sternotomy with cardiopulmonary bypass remains an option for patients with unfavorable anatomy. Minimally invasive right mini-thoracotomy approaches are available at select high-volume centers. Mitral Valve Replacement (MVR) with a mechanical prosthesis (St. Jude Medical, On-X) or biological bioprosthesis is the definitive surgical option for patients with concomitant severe MR, heavily calcified valves, or restenosis after prior BMV, with robotic-assisted MVR now available at select Indian and UAE centers for eligible patients.

PHASE 1 — REMOTE EVALUATION (2–4 weeks before travel):

The patient's journey begins with GAF Healthcare's remote medical review. The patient submits recent echocardiography reports, ECG, chest X-ray, blood work, and clinical history through GAF Healthcare's secure digital platform. A GAF-affiliated interventional cardiologist reviews the data, calculates the Wilkins Score, assesses MVA, and determines BMV candidacy. A personalized treatment plan, cost estimate, and hospital recommendation are issued within 48–72 hours.

PHASE 2 — ARRIVAL AND PRE-PROCEDURAL WORKUP (Day 1–2):

On arrival, the patient is received by a GAF Healthcare coordinator at the airport and transferred to the partner hospital. Day 1 involves outpatient consultations, repeat TTE (to confirm baseline hemodynamics), TEE (to definitively exclude LAA thrombus), 12-lead ECG, complete blood panel, and coagulation profile. If the patient has been on warfarin, INR is checked; if therapeutic anticoagulation was used to resolve LAA thrombus, this TEE confirms resolution. Anesthesia consultation is completed. Consent discussion includes specific risks of transseptal puncture, balloon-induced MR, pericardial tamponade, and stroke.

PHASE 3 — THE PROCEDURE (Day 2 or 3, approximately 60–120 minutes):

The procedure is performed in a dedicated cardiac catheterization laboratory under fluoroscopic and echocardiographic guidance. The patient is positioned supine, and femoral venous access is obtained under local anesthesia with conscious sedation (or general anesthesia if TEE guidance is used). Transseptal puncture is performed, the Inoue balloon is advanced across the mitral valve, and stepwise dilation is performed. After each inflation, the interventionalist evaluates MVA by echo and assesses MR grade. The procedure concludes when target MVA is achieved (≥1.5 cm²) without significant MR increase. Total procedural time is typically 60–120 minutes. Hemostasis is achieved with manual compression or a vascular closure device at the femoral access site.

PHASE 4 — IMMEDIATE POST-PROCEDURAL MONITORING (Day 2–4):

The patient is transferred to a monitored cardiac care unit (CCU) or high-dependency unit (HDU) for 12–24 hours. Continuous ECG monitoring, pulse oximetry, and hemodynamic assessment are maintained. A post-procedural TTE is performed within 24 hours to confirm MVA improvement, assess MR severity, and rule out pericardial effusion. If the patient is in sinus rhythm, anticoagulation strategy is reassessed. If in persistent atrial fibrillation, therapeutic anticoagulation (warfarin or a DOAC as per electrophysiology guidance) is continued. The femoral access site is assessed for hematoma or vascular complications. Diuretics are adjusted based on fluid balance. The patient is mobilized to sitting on Day 1 post-procedure and walking by Day 2.

PHASE 5 — HOSPITAL DISCHARGE (Day 3–4):

Discharge criteria include: hemodynamic stability, echocardiographic confirmation of adequate MVA, no significant MR, no pericardial effusion, and intact femoral access site. A detailed discharge summary, medication reconciliation sheet (including anticoagulation plan, rhythm medications, rheumatic fever prophylaxis), and follow-up echocardiography schedule (at 1 month, 6 months, and annually) are provided. GAF Healthcare coordinates the discharge paperwork and arranges the post-discharge accommodation.

PHASE 6 — POST-DISCHARGE RECOVERY AND FIT-TO-FLY WINDOW (Days 5–14):

Most patients are fit for light activity within 3–5 days of the procedure. The femoral access site requires 5–7 days for complete skin healing. International air travel is safe after 7–14 days, provided the patient is hemodynamically stable, there is no significant residual MR, and no thromboembolic or access-site complications are present. GAF Healthcare arranges a clinical review on Day 7–10, including a repeat TTE and INR check (if on warfarin), to formally clear the patient for travel. Patients requiring anticoagulation receive a medical letter and sufficient medication supply for their home journey.

RECOVERY MILESTONES:

• Day 1 post-procedure: Sitting up, liquid diet, ECG monitoring

• Day 2: Ambulation in room, solid diet, routine observations

• Day 3–4: Hospital discharge

• Day 5–7: Light daily activities at accommodation (walking, self-care)

• Day 7–10: Clinical review, TTE, INR check, fit-to-fly assessment

• Week 2–4: Return to sedentary work (remote work possible by week 2)

• Month 1: Cardiology follow-up (can be done with home cardiologist with reports forwarded to GAF Healthcare)

• Month 3–6: Repeat echocardiography to confirm sustained MVA improvement